1Kim DY, Kim JH, Lee SH, et al. Phase Ⅱ study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer[ J]. Ann Oncol, 2003, 14 (3) :383 -387.
3AI-Batran SE, Jaeger E, Jaeger D, et al. Oxaliplatin, 5-fluorouracil and leucovorin every two weeks in patients with advanced gastric cancer; preliminary results of a muhieenter, phase Ⅱ study[J]. Proc Am Soc Clin Oncol, 2003, 22: a1128.
4Cavanna L, Artioli F, Codignola C, et al. Oxaliplatin, in combination with 5 -fluorouracil ( 5-Fu ) and leucovorin ( LV ) in patients with advanced or metaststic gastric cancer(MGC) [ J ]. Am J Clin Oncol, 2006, 29(4):371 -375.
5Waters JS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: resuits of a randomized trial [ J ]. Br J Cancer, 1999, 80 (1-2) : 269 - 272.
6Webb A, Cunningham D, Scafffe JH, et al. Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluerouracil, doxorubicin and mefhotrexate in advanced esophagogastric cancer[ J ]. J Clin Oncol, 1997,15 ( 1 ) :261 - 267.
7Cocconi G, Carlini P, Gamboni A, et al. Cisplatin, epirubicin, leucovorin and 5-fluorouracil(PELF) is more active than 5-fluerouracil, doxorubicin and mefhotrexate (FAMTX) in advanced gastric carcinoma[ J ]. Ann Oncol, 2003,14 (8) : 1258 - 1263.
9Cunningham D, Rao S, Starling N, et al. Randomised multicentie phase Ⅲ study comparing capecitabing with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: The REAL 2 trial[J]. Proc Am Soc Clin Oncol, 2006, 24:182.
2De Gramont A, Krulik M, Cady J, et al. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer.Eur J Cancer Clin Oncol, 1988, 24:1499-1503.
3Ajani JA. Current status of therapy for advanced gastric carcinoma.Oncology, 1998, 12:99-102.
4Raymond E, Charley SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol, 1998, 9:1053-1071.
5De Gramont A, Figer A, Seymonr M, et al. Leucovorin and fluorouracil with or without oxaliplatin as frist-line treatment in advanced colorectal cancer. J Clin Oncol, 2000,18:2938-2947.
6De Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly highdose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer : a French intergroup study. J Clin Oncol,1997, 15:808-815.
7Richard P, Lawrence RC, Willianm JH, et al. Ed. Cancer Management: A Multidisciplinary Approach (Eighth Edition) [M]. New Yoek: CMP Healthcare Media, Oncology Pulishing. 2004. 269～271.
8Sumpter KA, Harper-Wyrme C, Cunningham D, et al. Randomised, multicenter phase Ⅲ study comparing capecitabine with 5FU and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: Confirmation of dose escalation [Abstract 1031][J]. Proc Am Soc Clin Oncol, 2003, 22:257.
9Waters JS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial [J]. BrJ Cancer. 1999, 80 (1-2):269～272.
10Cocconi G, Carlini P, Gamboni A, et al. Cisplatin, eprubicin, leucovorin and 5-fluorouracil (PELF) is mor active than 5-fluorouracil, doxorubic and methotrexate (FAMTX) in advanced gastric carcinoma[J]. Ann Oncol, 2003, 14(8):1258～1263.
